[ad_1]
Logo of world-wide biopharmaceutical organization Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage, in close proximity to Agen, France March 29, 2018.
Regis Duvignau | REUTERS
Bristol Myers Squibb mentioned on Tuesday it will obtain radiopharmaceutical firm RayzeBio for about $4.1 billion.
Bristol stated it will pay $62.50 for each share of RayzeBio in hard cash, representing a high quality of 104% to the stock’s previous shut.
RayzeBio shares ended up halted in advance of the offer announcement.
This story is acquiring. Make sure you examine back again for updates.
[ad_2]
Source website link
